N- palmitoyl- S- (2,3- bis(palmitoyloxy)propyl)cysteinyl- seryl- lysyl- lysyl- lysyl- lysine

structure given in first source; activates superoxide formation & lysozyme release in human neutrophils

Also Known As:

N-palmitoyl-5,6-dipalmitoylcysteinyl-seryl-lysine(4); P3C-SK4; P3CSK4; Pam(3)-Cys-Ser-(Lys)(4); Pam(3)-Cys-Ser-(Lys)4; Pam(3)-Cys-Ser-Lys(4); Pam3Cys; Pam3Cys-Ser-(Lys)4; tripalmitoyl-cysteinyl-seryl-lysine(4)

Networked: 28 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Niebuhr, Margarete: 2 articles (05/2015 - 10/2010)
2.	Werfel, Thomas: 2 articles (05/2015 - 10/2010)
3.	Buhre, Wolfgang F: 2 articles (03/2015 - 01/2009)
4.	Flier, Suzanne: 2 articles (03/2015 - 01/2009)
5.	Hoefer, Imo E: 2 articles (03/2015 - 01/2009)
6.	Pasterkamp, Gerard: 2 articles (03/2015 - 01/2009)
7.	Versteeg, Dik: 2 articles (03/2015 - 01/2009)
8.	Gupta, Suman: 2 articles (07/2012 - 10/2011)
9.	Sane, Shraddha A: 2 articles (07/2012 - 10/2011)
10.	Shakya, Nishi: 2 articles (07/2012 - 10/2011)

Related Diseases

1.	Visceral Leishmaniasis (Kala Azar) 10/01/2011 - "Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis." 10/01/2011 - "Prophylactic potential of synthetic bacterial lipopeptide and a TLR2 agonist, Pam3Cys was first evaluated against experimental visceral leishmaniasis in rodent model. " 07/01/2012 - "Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis."
2.	Necrosis 04/01/2011 - "PBMCs were stimulated with lipopolysaccharide (LPS) and Pam3Cys for the release of tumour necrosis factor-alpha (TNFα). " 07/01/2005 - "Co-administration of Abeta1-40 with LPS or Pam3Cys led to an additive release of nitric oxide (NO) and tumour necrosis factor alpha (TNF-alpha). " 03/01/2015 - "We assessed in-vivo TLR-2 and TLR-4 expression and ex-vivo monocyte responsiveness to TLR-2 and TLR-4 ligands, measured by Pam3Cys and lipopolysaccharide (LPS)-induced interleukin (IL)-6 and IL-8, and tumour necrosis factor alpha (TNF-α) secretion until 24 h after surgery. " 04/01/2011 - "1,25(OH)(2) D(3) decreased interleukin (IL)-6 and tumour necrosis factor (TNF)-α release by PBMC stimulated with tripalmitoyl-S-glycerylcysteine (Pam3Cys) or lipopolysaccharide (LPS). "
3.	Inflammation (Inflammations) 08/01/2014 - "The role of TLR2 signaling was confirmed by intranasal treatment of wildtype mice with the agonist Pam3Cys, which decreased inflammation and reduced bacterial shedding and transmission. " 01/01/2018 - "Here, we show that TLR2 activation by synthetic lipopeptides, Pam2Cys, and Pam3Cys specifically, variably influenced inflammation and subsequent induction of PTB. " 04/01/2008 - "To determine the role of MAPKs in TLR- induced corneal inflammation, we stimulated human corneal epithelial (HCE) cells with TLR2 ligands, tripalmitoyl-S-glycero-Cys-(Lys)4 (Pam3Cys) or inactivated Staphylococcus aureus, and examined the time course of expression of MAPKs and the effect of MAPK inhibition on IkBalpha degradation and CXC chemokine production. " 04/01/2013 - "The results show that dermal exposure to TLR4 ligand lipopolysaccharide (LPS) or TLR2 ligand Pam3Cys suppresses asthmatic responses by reducing airway hyperreactivity, mucus production, Th2-type inflammation in the lungs, and IgE antibodies in serum in a dose-dependent manner. "
4.	Infections 10/01/2010 - "Our findings show evidence for a functional TLR-2/TLR-1 signalling profile in HPKs upon stimulation with Pam3Cys contributing to the defense against bacterial skin infections." 11/01/2008 - "donovani infection of monocytes (cell line THP-1, and monocytes derived from human peripheral blood) on Pam3cys (TLR2 ligand) and lipopolysaccharide (TLR4 ligand) stimulated production of IL-12p40 and IL-10. " 01/01/2023 - "We studied the capacity of lidocaine to modulate cytokine secretion of mouse and human myeloid cell lines activated by different cytokines or Toll Like Receptor (TLR) ligands (flagellin (FliC), Lipopolysaccharide (LPS), Polyinosinic:polycytidylic acid (Poly I:C) and N-Palmitoyl-S- [2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine x 3HCl (Pam3Cys-SKKKK)) or by Severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) infection to epithelial cells. "
5.	Sepsis (Septicemia) 06/01/2013 - "We investigated whether the dysfunction of dendritic cells (DC) that develops during polymicrobial sepsis is mimicked by systemic administration of the Toll-like receptor (TLR) 4 agonist lipopolysaccharide (LPS) or of the TLR2 agonist Pam3-Cys-Ser-Lys4 (P3CSK4). " 01/15/2011 - "Because deranged endothelial function and coagulation pathways contribute to sepsis-induced organ failure, we studied the effects of bacterial lipoprotein TLR2 agonists, including peptidoglycan-associated lipoprotein, Pam3Cys, and murein lipoprotein, on endothelial function and coagulation pathways in vitro and in vivo. "

Related Drugs and Biologics

1.	miltefosine (Impavido)
2.	Lipopeptides
3.	Lipopolysaccharides
4.	Ligands
5.	Toll-Like Receptors (Toll-Like Receptor)
6.	Poly I-C
7.	Interleukin-8 (Interleukin 8)
8.	Vaccines
9.	Peptidoglycan (Murein)
10.	Interleukins

Related Therapies and Procedures

1.	Microspheres (Microsphere)
2.	Immunotherapy